Research posters showcasing the latest advancements in spatial proteomics
Video presentations
Video presentations
Research posters showcasing the latest advancements in spatial proteomics
Video presentations
Explore our collection of video presentations of posters highlighting the benefits of the in situ proximity ligation assay. These presentations showcase various collaborative projects involving Navinci and offer detailed insights into recent advancements in the field.
Video presentations
Explore our collection of video presentations of posters highlighting the benefits of the in situ proximity ligation assay. These presentations showcase various collaborative projects involving Navinci and offer detailed insights into recent advancements in the field.
PD-1/PD-L1 interaction as a superior predictor for response to immune checkpoint therapy
Patrick Micke and Carina Strell’s groups investigated 305 clinical samples of NSCLC patients using isPLA in addition to the classical IHC.
Integrating in situ proximity ligation assay with multiplexed immunofluorescence imaging
Charlotte Stadler’s group at SciLife-KTH used the PD1/PDL1 interaction as part of a multiplex IF panel with the aim to deep-phenotype the TME.
Combining in situ proximity ligation assay and multiplex immunofluorescence imaging
In collaboration with Navinci, Arne Christians and his colleagues from Canopy Bioscience integrated isPLA with the CellScape multiplex cycIF platform.
Defining PD1/PD-L1 interactions in the tumor microenvironment
Dr. Arutha Kulasinghe’s group at University of Queensland performed spatial profiling on Akoya’s Phenocycler Fusion with Navinci’s isPLA technology.
High-plex Tumor-immune Phenotyping and Checkpoint Interactions
In partnership with Akoya Biosciences and Navinci, Arutha Kulasinghe’s group at the University of Queensland integrated PD1/PD-L1 isPLA with the PhenoCode Signature Immune Panel to study protein-protein interactions in the broader context of the TME.
PD-1/PD-L1 interaction as a superior predictor for response to immune checkpoint therapy
Patrick Micke and Carina Strell’s groups investigated 305 clinical samples of NSCLC patients using isPLA in addition to the classical IHC.
Integrating in situ proximity ligation assay with multiplexed immunofluorescence imaging
Charlotte Stadler’s group at SciLife-KTH used the PD1/PDL1 interaction as part of a multiplex IF panel with the aim to deep-phenotype the TME.
Combining in situ proximity ligation assay and multiplex immunofluorescence imaging
In collaboration with Navinci, Arne Christians and his colleagues from Canopy Bioscience integrated isPLA with the CellScape multiplex cycIF platform.
Defining PD1/PD-L1 interactions in the tumor microenvironment
Dr. Arutha Kulasinghe’s group at University of Queensland performed spatial profiling on Akoya’s Phenocycler Fusion with Navinci’s isPLA technology.
High-plex Tumor-immune Phenotyping and Checkpoint Interactions
In partnership with Akoya, Navinci integrated PD1/PD-L1 isPLA with the PhenoCode Signature Immune Panel to study protein-protein interactions in the broader context of the TME.